IP Verse

Long Lasting Effect Of New Botulinum Toxin Formulations - EP3079714

The patent EP3079714 was granted to Medy TOX on Nov 25, 2020. The application was originally filed on Dec 12, 2014 under application number EP14815207A. The patent is currently recorded with a legal status of "Revoked".

EP3079714

MEDY TOX
Application Number
EP14815207A
Filing Date
Dec 12, 2014
Status
Revoked
Nov 25, 2022
Grant Date
Nov 25, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALDERMA HOLDINGAug 24, 2021PLASSERAUDADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP2692350
INTERNATIONAL-SEARCH-REPORTUS2003118598
INTERNATIONAL-SEARCH-REPORTUS2006018931
INTERNATIONAL-SEARCH-REPORTWO2007044809
INTERNATIONAL-SEARCH-REPORTWO2009008595
INTERNATIONAL-SEARCH-REPORTWO2012048854
OPPOSITIONWO2012134240

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- DRESSLER D, "Five-year experience with incobotulinumtoxinA (Xeomin((R)) ): the first botulinum toxin drug free of complexing proteins.", EUROPEAN JOURNAL OF NEUROLOGY : THE OFFICIAL JOURNAL OF THE EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES MAR 2012, (201203), vol. 19, no. 3, ISSN 1468-1331, pages 385 - 389, XP002736596 [A] 1-27 * abstract * * page 388 *
OPPOSITION- Field Malgorzata, Et Al, "AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin content and potential implications for duration of response in patients", Toxins, (20181213), vol. 10, no. 535, pages 1 - 14, XP055864107-
OPPOSITION- Matarasso Alan, Et Al, "Effective use of Botox for lateral canthal rhytids", Aesthetic Journal, (20010101), vol. 21, no. 1, pages 61 - 63, XP055864116-
OPPOSITION- Trindade De Almeida Ada R, Et Al, "Glabellar contraction patterns: a tool to optimize botulinum toxin treatment", Dermatologic Surgery, (20120101), vol. 38, no. 9, pages 1 - 10, XP055864110-
OPPOSITION- Yamauchi Paul S, "Selection and preference for botulinum toxins in the management of photoaging and facial lines: patient and physician considerations", Patient preference and adherence, (20100101), pages 345 - 354, XP055864119-
OPPOSITION- ASCHER, B. et al., "International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)-part I: upper facial wrinkles", Journal of the European Academy of Dermatology and Venereology, (20100000), vol. 24, no. 11, doi:10.1111/j.1468-3083.2010.03631.x, pages 1278 - 1284, XP055562997
OPPOSITION- ASCHER, B. et al., "International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)-Part II: Wrinkles on the middle and lower face, neck and chest", Journal of the European Academy of Dermatology and Venereology, (20100000), vol. 24, no. 11, doi:10.1111/j.1468-3083.2010.03728.x, pages 1285 - 1295, XP055563004

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents